Results 241 to 250 of about 32,347 (265)

Endosomal Trafficking as a Determinant of Antifungal Tolerance in the Pathogenic Fungus Candida albicans

, 2018
openaire   +1 more source

Defining the frontiers between antifungal resistance, tolerance and the concept of persistence [PDF]

Drug Resistance Updates, 2015
A restricted number of antifungal agents are available for the therapy of fungal diseases. With the introduction of epidemiological cut-off values for each agent in important fungal pathogens based on the distribution of minimal inhibitory concentration (
Eric Delarze, Dominique Sanglard
exaly   +6 more sources

Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris [PDF]

MSphere, 2019
The enigmatic yeast Candida auris has emerged over the last decade and rapidly penetrated our consciousness. The global threat from this multidrug-resistant yeast has generated a call to arms from within the medical mycology community.
Ryan Kean, Gordon Ramage
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations

Clinical Therapeutics, 2003
A systematic review was performed to compare the effectiveness and tolerability of lipid-based amphotericin B (AmB) formulations and conventional AmB in the treatment of systemic fungal infections.The literature and unpublished studies were searched using MEDLINE, EMBASE, Biological Abstracts, AIDSLINE, CANCERLIT, CRD database, Cochrane Controlled ...
Barrett, Jane P., Vardulaki, Katerina A., Conlon, Christopher, Cooke, Jonathan; id_orcid 0000-0001-5016-9048, Daza-Ramirez, Pascual, Evans, E. Glyn V, Hawkey, Peter M., Herbrecht, Raoul, Marks, David I., Moraleda, Jose M., Park, Gilbert R., Senn, Stephen J., Viscoli, Claudio   +12 more
openaire   +4 more sources

Non-antifungal medications administered during fungal infections drive drug tolerance and resistance in Candida albicans

Journal of Medical Microbiology
Introduction. Fungal infections are increasingly concerning, particularly in immunocompromised patients. These patients often suffer from comorbidities and receive multiple, non-antifungal medications.Gap Statement.
Pinkus Tober-Lau, Judith Berman
exaly   +3 more sources

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy

Expert Opinion on Drug Metabolism & Toxicology, 2017
Triazole antifungal agents are prescribed to treat invasive fungal infections in neutropenic and non-neutropenic patients. These antifungal agents are substrates and inhibitors of cytochrome P450 (CYP). Genetic polymorphisms in CYP2C9, CYP2C19 and CYP3A5 can lead to large population-specific variations in drug efficacy and safety, optimal dosing, or ...
Jarrett R, Amsden, Paul O, Gubbins
openaire   +2 more sources

Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy

Supportive Care in Cancer, 2004
The effectiveness of amphotericin B oral suspension versus nystatin oral suspension for the prevention of oral colonization by Candida in hematopoietic cell transplant (HCT) patients was examined.Prior to hematopoietic cell infusion, 40 patients receiving systemic fluconazole for prophylaxis were randomized to receive either amphotericin B oral ...
Joel B, Epstein, Edmond L, Truelove, Kimberly, Hanson-Huggins, Lloyd A, Mancl, Alice, Chen, Oliver W, Press, Stephen H, Petersdorf, Thomas R, Fritsche, Joshua D, Epstein   +8 more
openaire   +2 more sources

Resistance and tolerance mechanisms to antifungal drugs in fungal pathogens

Mycologist, 2003
Fungal pathogens are using several mechanisms to circumvent the inhibitory actions of antifungal drugs. The variety of these mechanisms was revealed in recent years by several laboratories with molecular approaches. Besides the identification of genes involved in antifungal drug resistance and the discovery of alternative pathways of resistance (i.e ...
openaire   +1 more source

Safety and Tolerability of High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis

Pediatric Infectious Disease Journal, 2014
Children with hematologic malignancies are at an increased risk of invasive fungal infections and a greater risk has been seen with exposure to building construction. Prophylaxis with high-dose (IV) liposomal amphotericin B (L-AmB) 10 mg/kg once weekly was initiated in our high risk children based on previous pharmacokinetic studies.
Elizabeth O, Hand, Meenakshi R, Ramanathan   +1 more
openaire   +2 more sources

Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects

The Journal of Clinical Pharmacology, 2018
AbstractLetermovir is a human cytomegalovirus terminase inhibitor for cytomegalovirus infection prophylaxis in hematopoietic stem cell transplant recipients. Posaconazole (POS), a substrate of glucuronosyltransferase and P‐glycoprotein, and voriconazole (VRC), a substrate of CYP2C9/19, are commonly administered to transplant recipients.
William L, Marshall, Jacqueline B, McCrea, Sreeraj, Macha, Karsten, Menzel, Fang, Liu, Arne, van Schanke, Joanna I Udo, de Haes, Azra, Hussaini, Heather R, Jordan, Melissa, Drexel, Bhavna S, Kantesaria, Christine, Tsai, Carolyn R, Cho, Ellen G J, Hulskotte, Joan R, Butterton, Marian, Iwamoto   +15 more
openaire   +2 more sources